A study by researchers at Vanderbilt University Medical Center has strengthened the link between thyroid function and atrial fibrillation (AF), an irregular heart rhythm that increases the risk of stroke and other heart-related complications.

The phenome-wide association study scanned the medical records of more than 37,000 people for an association between genetically determined variation in thyroid stimulating hormone levels (a measure of thyroid function) and AF risk.

Previous observational studies have found that subclinical hyperthyroidism, an overactive thyroid which does not meet the clinical threshold for diagnosis or treatment, nevertheless can increase the risk of AF. But whether to treat subclinical hypo- or hyperthyroidism to reduce AF risk remains a matter of debate in the medical community.

The current study, published today in the journal JAMA Cardiology, found that genetically determined variations in thyroid function, even those which fall within a physiologically accepted “normal” range, still can increase the risk for AF.

The decision to treat subclinical thyroid disease should account for this new evidence, as “antithyroid medications to treat hyperthyroidism may reduce AF risk (while) thyroid hormone replacement for hypothyroidism (low thyroid function) may increase AF risk,” the researchers concluded.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Before you post, please prove you are sentient.

what is 8 + 4?

Explore More

New genetic cause of obesity could help guide treatment

Scientists have discovered a new cause of why people who lack a specific blood group are genetically predisposed to be overweight or obese. A team of international researchers, led by

Hypothyroidism in pregnant mothers linked to ADHD in their children

Low levels of key, body-regulating chemicals in mothers during the first three months of pregnancy may interfere with the baby’s brain development, a large American study shows. These chemicals, or

Fat-secreted molecule lowers response to common cancer treatment

Leptin, a molecule produced by fat cells, appears to cancel out the effects of the estrogen-blocking therapy tamoxifen, a drug commonly used to treat and prevent breast cancers, suggests a